Showing 81-90 of 9511 results for "".
- Cherry Angiomas Linked to NF1-Related Vascular Changes: Studyhttps://practicaldermatology.com/news/cherry-angiomas-linked-to-nf1-related-vascular-changes-study/2488158/Cherry angiomas may be a previously underrecognized vascular manifestation of neurofibromatosis type 1 (NF1), according to findings from a prospective comparative study in JAMA Dermatology. Investigators evaluated 259 participants (102 individuals with confirmed NF1 and 157 contro
- LEO Pharma Acquires Worldwide Rights to Dersimelagon for EPP, XLPhttps://practicaldermatology.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-epp-xlp/2488131/LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma, adding a late-stage investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to its rare dermatology pipeline. Under the agreement, LEO Pharma w
- AbbVie Names 34 Immunology Scholarship Recipients for 2026https://practicaldermatology.com/news/abbvie-names-34-immunology-scholarship-recipients-for-2026/2488127/AbbVie has announced 34 recipients of its 2026 AbbVie Immunology Scholarship, according to a news release, marking the 10th year of a program designed to support students living with chronic inflammatory diseases as they pursue higher education. Since the scholarship launched in 2016, AbbV
- AI Beauty Tools May Favor Narrower Facial Aesthetic Standards: Supplementhttps://practicaldermatology.com/news/ai-beauty-tools-may-favor-narrower-facial-aesthetic-standards-supplement/2488121/Artificial intelligence (AI) is emerging as another influence on facial aesthetic standards, potentially affecting how patients perceive attractiveness and approach cosmetic procedures, according to brief review in The Journal of Craniofacial Surgery. The authors explored how AI s
- GLP-1 Receptor Agonists Not Linked to Increased Melanoma Risk in T2Dhttps://practicaldermatology.com/news/glp-1-receptor-agonists-not-linked-to-increased-melanoma-risk-in-t2d/2488105/GLP-1 receptor agonist (GLP-1RA) therapy was not associated with an increased risk of melanoma among adults with type 2 diabetes (T2D) in a large target trial emulation published in Diabetes, Obesity and Metabolism. GLP-1RA Use and Skin Cancer Risk Investigators used TriN
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- Three-Part Acne Scar Protocol Shows Progressive Changes Through 139 Dayshttps://practicaldermatology.com/news/three-part-acne-scar-protocol-shows-progressive-changes-through-139-days/2488104/A multimodal protocol combining subcision, injectable treatment, and fractional laser therapy was associated with reductions in facial atrophic acne scar dimensions in a prospective case series published in Biomedicines. Ultrasound Tracks Changes Through 139 Days The stud
- Treatment Sessions Linked to ABNOM Clearance in Laser Meta-Analysishttps://practicaldermatology.com/news/treatment-sessions-linked-to-abnom-clearance-in-laser-meta-analysis/2488080/Treatment session number was more strongly associated with clearance of acquired bilateral nevus of Ota-like macules (ABNOM) than whether patients received picosecond (PS) or Q-switched (QS) laser treatment, according to a new study. Published in Lasers in Medical Science, the ana
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://practicaldermatology.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- New Photoimmunotherapy Approach Targets T Cells and Tumor Antigenshttps://practicaldermatology.com/news/study-new-photoimmunotherapy-approach-targets-t-cells-and-tumor-antigens/2488067/A new activatable photoimmunotherapy platform may enable more selective depletion of pathogenic cells while limiting inflammatory effects associated with existing PIT approaches, according to new research. Photoimmunotherapy